- AuthorisedTherapeutic exploratory (Phase II)
A phase 2 trial of BMS-986365 in mCSPC patients with suboptimal PSA-response after 7 months of Androgen Deprivation Therapy (ADT) plus Androgen Receptor Pathway Inhibition (ARPI).
This study looks at a new drug, BMS-986365, for men with prostate cancer that has spread. It's for those who haven't responded well enough to their current hormone treatment. We want to see if this new drug can help lower PSA levels, which is a marker for prostate cancer activity.
For: Metastatic Castrate Sensitive Prostate Cancer - mCSPCGermany - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
This study looks at a new drug, BMS-986365, for men with prostate cancer that has spread and is no longer responding to hormone treatment. We want to see if it works better and is safer than standard treatments chosen by doctors.
For: Metastatic Castration-resistant Prostate CancerUnited States · Argentina · Australia